Precision Pathology Co-Pilot & Workflow
OncoGemma integrates high-resolution Whole Slide Imaging (WSI) with a fine-tuned clinical agent. From instant molecular subtyping to chemotoxicity prediction, it empowers pathologists with precision oncology insights.
Launching at India AI Impact Summit, Delhi (Feb 2026)
High-res H&E and IHC slide upload with instant quality control
Proprietary Graph Attention Autoencoders analyze morphology & risk
Agentic AI contextualizes findings with latest clinical research
Automated generation of subtyping, toxicity, and treatment plans
Instantly predicts molecular subtypes from H&E slides. Identifies overexpression of key genes and mutation status (e.g., TP53, PD-L1) without waiting for wet-lab results.
Powered by our Graph Attention Autoencoder, this module stratifies patients by risk level, predicting disease progression and survival outcomes.
Predicts patient-specific risk for chemotherapy and immunotherapy toxicity, enabling oncologists to optimize dosage and regimen safety.
A fine-tuned version of MedGemma on proprietary histopathology datasets. It acts as an active assistant, taking notes, answering queries, and retrieving reference studies.
Integrated clinical chat allows pathologists and oncologists to discuss cases directly on the slide, with AI-summarized context and decision support.
Automated quantification of tumor burden percentage and location, streamlining the reporting process for neoadjuvant therapy evaluation.
We are fine-tuning OncoGemma to address the specific healthcare challenges of the Global South. We are actively seeking partners to validate our models on diverse Indian datasets.
* Proprietary models including Graph Attention Autoencoder & OncoGemma are currently in closed beta.
